Mason Street Advisors’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-27,118
| Closed | -$3.22M | – | 514 |
|
|
2020
Q4 | $3.22M | Sell |
27,118
-17
| -0.1% | -$1.83K | 0.05% | 390 |
|
|
2020
Q3 | $2.37M | Sell |
27,135
-477
| -2% | -$41.7K | 0.05% | 446 |
|
|
2020
Q2 | $2.47M | Buy |
27,612
+654
| +2% | +$66.1K | 0.05% | 407 |
|
|
2020
Q1 | $2.69M | Hold |
26,958
| – | – | 0.06% | 312 |
|
|
2019
Q4 | $3.1M | Buy |
26,958
+333
| +1% | +$40.3K | 0.06% | 375 |
|
|
2019
Q3 | $3.36M | Sell |
26,625
-669
| -2% | -$84.9K | 0.07% | 315 |
|
|
2019
Q2 | $3.29M | Buy |
27,294
+170
| +0.6% | +$16.7K | 0.07% | 324 |
|
|
2019
Q1 | $2.37M | Buy |
27,124
+52
| +0.2% | +$4.73K | 0.05% | 482 |
|
|
2018
Q4 | $2.71M | Buy |
27,072
+523
| +2% | +$54.9K | 0.07% | 329 |
|
|
2018
Q3 | $3.04M | Sell |
26,549
-227
| -0.8% | -$23.5K | 0.06% | 344 |
|
|
2018
Q2 | $2.4M | Buy |
26,776
+11,949
| +81% | +$1.01M | 0.05% | 447 |
|
|
2018
Q1 | $1.08M | Buy |
14,827
+1,090
| +8% | +$74.8K | 0.02% | 816 |
|
|
2017
Q4 | $798K | Buy |
13,737
+414
| +3% | +$21.8K | 0.02% | 900 |
|
|
2017
Q3 | $598K | Buy |
13,323
+385
| +3% | +$16K | 0.01% | 968 |
|
|
2017
Q2 | $511K | Buy |
12,938
+778
| +6% | +$32K | 0.01% | 992 |
|
|
2017
Q1 | $493K | Buy |
12,160
+872
| +8% | +$34.1K | 0.01% | 991 |
|
|
2016
Q4 | $454K | Buy |
11,288
+728
| +7% | +$27.4K | 0.01% | 994 |
|
|
2016
Q3 | $382K | Buy |
10,560
+582
| +6% | +$20K | 0.01% | 1009 |
|
|
2016
Q2 | $289K | Buy |
9,978
+939
| +10% | +$28.4K | 0.01% | 1051 |
|
|
2016
Q1 | $316K | Buy |
9,039
+864
| +11% | +$27.9K | 0.01% | 993 |
|
|
2015
Q4 | $264K | Buy |
8,175
+678
| +9% | +$22K | 0.01% | 1019 |
|
|
2015
Q3 | $242K | Buy |
7,497
+358
| +5% | +$13.5K | 0.01% | 1018 |
|
|
2015
Q2 | $295K | Buy |
7,139
+302
| +4% | +$12.7K | 0.01% | 983 |
|
|
2015
Q1 | $307K | Buy |
6,837
+233
| +4% | +$9.74K | 0.01% | 960 |
|
|
2014
Q4 | $247K | Buy |
6,604
+186
| +3% | +$6.81K | ﹤0.01% | 1437 |
|
|
2014
Q3 | $224K | Sell |
6,418
-125
| -2% | -$4.46K | ﹤0.01% | 1448 |
|
|
2014
Q2 | $231K | Buy |
6,543
+207
| +3% | +$6.92K | ﹤0.01% | 1439 |
|
|
2014
Q1 | $206K | Sell |
6,336
-1,860
| -23% | -$71.1K | ﹤0.01% | 1442 |
|
|
2013
Q4 | $345K | Buy |
8,196
+640
| +8% | +$26.3K | ﹤0.01% | 1378 |
|
|
2013
Q3 | $301K | Buy |
7,556
+479
| +7% | +$20.1K | ﹤0.01% | 1207 |
|
|
2013
Q2 | $293K | Buy |
+7,077
| New | +$287K | ﹤0.01% | 1143 |
|
Other funds holding HAE
Mason Street Advisors's HAE Position: Q1 2021 in Review
Mason Street Advisors sold out of Haemonetics (HAE) in Q1 2021, closing a stake of 27,118 shares — an estimated $3.22M sold.
Mason Street Advisors first reported a position in HAE in Q2 2013 and held it in 31 quarters. The position peaked at $3.36M in Q3 2019. 296 funds tracked by Wall St. Rank hold HAE as of Q1 2021.
- Mason Street Advisors reported no remaining Haemonetics position as of Q1 2021 after selling out during the quarter.
- Mason Street Advisors sold 27,118 Haemonetics shares in Q1 2021, an estimated $3.22M.
- Mason Street Advisors first reported a position in Haemonetics in Q2 2013 and held it in 31 quarters.
- Mason Street Advisors's Haemonetics position peaked at $3.36M in Q3 2019.
- 296 funds tracked by Wall St. Rank held Haemonetics as of Q1 2021.
Based on Mason Street Advisors's 13F filing for Q1 2021, filed 14 May 2021.